3-(5-Dimethylamino-1-naphthalenesulphonyl)-2-(3-pyridyl)thiazolidine (YHI-1), a synthetic analogue of D-cysteinolic acid isolated from sardines (Sardinops melanostictus), was found to be a specific inhibitor of human immunodeficiency virus type 1 (HIV-1) replication in various cell cultures. YHI-1 inhibited HIV-1IIIB replication with a 50% effective concentration (EC50) of 3.35, 10.23 and 4.61 μM in MT-4 cells, peripheral blood mononuclear cells and MAGI-CCR5 cells, respectively. However, no antiviral activity was observed with non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, such as nevirapine-resistant HIV-1HE/NEV and MKC-442-resistant HIV-1IIIB-R, or with HIV-2ROD or SIVMAC. YHI-1 failed to inhibit reverse transcriptase (RT) activity in vitro with different template–primer systems. Time-of-addition experiments, the failure to inhibit NNRTI-resistant strains and the failure to show in vitro activity against RT suggest that a metabolite of YHI-1 inside the cell acts like an NNRTI. Thus, YHI-1 seems to belong to a new class of HIV-1 inhibitor and is a good candidate for further development.
BabaMDe ClercqETanakaHUbasawaMTakashimaHSekiyaKNittaIUmezuKNakashimaHMoriSShigetaSWalkerRT & MiyasakaT (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA88:2356–2360.
2.
BabaMShigetaSYuasaSTakashimaHSekiyaKUbasawaMTanakaHMiyasakaTWalkerRT & De ClercqE (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobial Agents and Chemotherapy38:688–692.
3.
BacollaAShihC-KRoseJMPirasGWarrenTCGrygonCAIngrahamRHCousinsRCGreenwoodDJRichmanDChengY-C & GriffinJA (1993) Amino acid substitutions on HIV-1 reverse transcriptase with corresponding residues from HIV-2. Journal of Biological Chemistry268:16571–16577.
4.
BardosTJSchinaziRFLingK-HJ & HeiderAR (1992) Structure–activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy36:108–114.
5.
ChackerianBLongEMLuciwPA & OverbaughJ (1997) HIV-1 co-receptors participate in post-entry stages of the virus replication cycle and function in SIV infection. Journal of Virology71:3932–3939.
6.
CheesemanSHHavlirDMcLaughlinMMGreenoughTCSullivanJLHallDHattoxSESpectorSASteinDSMyersM & RichmanDD (1995) Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology8:141–151.
7.
ColosoMRHirschbergerLL & StipanukHM (1991) Uptake and metabolism of L-2-oxo-[35S]thiazolidine-4-carboxylate by rat cells is slower than that of L-[35S]cysteine or L-[35S]methionine. Journal of Nutrition121:1341–1348.
8.
CraginWDJonesDA & ShibamotoT (1989) Metabolism of N-nitroso-1,3-thiazolidine in the rat. Food and Chemical Toxicology27:105–110.
9.
DaveyJRTChaittDGReedGFFreimuthWWHerpinBRMetcalfJAEastmanPSFalloonJKovacsJAPolisMAWalkerREHasurHBoyleJColemanSCoxSRWathenLDaenzerCL & LaneHC (1996) Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents and Chemotherapy40:1657–1664.
10.
GoldmanMENunbergJHO'BrienJAQuinteroJCSchleifWAFreundKFGaulSLSaariWSWaiJSHoffmanJMAndersonPSHupeDJEminiEA & SternAM (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA88:6863–6867.
11.
GrosaGCaputoOCerutiM & BiglinoG (1992) Metabolism of 7-(1,3-thiazolidin-2-ylmethyl)theophylline by rat liver microsomes. Evidence for a monooxygenase-dependent step in 1,3-thiazolidine ring cleavage. Drug Metabolism and Disposition20:742–746.
12.
IjichiKFujiwaraMHanasakiYWatanabeHKatsuuraKTakayamaHShirakawaSSakaiSIShigetaSKonnoKYokotaT & BabaM (1995) Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl N,N-dialkylcarbamate derivatives. Antimicrobial Agents and Chemotherapy39:2337–2340.
13.
KimptonJ & EmermanM (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galac-tosidase gene. Journal of Virology66:2232–2239.
14.
KohlstaedtLAWangJFriedmanJMRicePA & SteitzTA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science256:1783–1790.
15.
MerluzziVJHargraveKDLabadiaMGrozingerKSkoogMWuJCShihCKEckneKHattoxSAdamsJRosenthalASFaanesREcknerRJKoupRA & SullivanJL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science250:1411–1413.
16.
NakashimaHShojiYKimS-GShimadaJMizushimaYItoMYa mamotoN & TakakuH (1994) Anti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligodeoxynucleotides: penetration and localization of oligodeoxynucleotides in HIV-1-infected MOLT-4 cells. Nucleic Acid Research22:5004–5010.
17.
NunbergJHSchleifWABootsEJO'BrienJAQuinteroJCHoffmanJMEminiEA & GoldmanME (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Journal of Virology65:4887–4892.
18.
NunoyaK-IYokoiTKimuraKKodamaTFunayamaMInoueKNagashimaKFunaeYShimadaNGreenC & KamatakiT (1996) (+)-Cis-3,5-dimethyl-2(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics277:768–774.
19.
PauwelsRBalzariniJBabaMSnoeckRScholsDHerdewijnPDesmyterJ & De ClercqE (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods20:309–321.
20.
PauwelsRAndriesKDesmyterJScholsDKuklaMJBreslinHJRaeymaeckersAGelderJVWoestenborghsRHeykantsJSchellekensKJanssenMACDe ClercqE & JanssenPAJ (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature343:470–474.
21.
PauwelsRAndriesKDebyserZDaelePVScholsDStoffelsPVreeseKDWoestenborghsRVandammeA-MJanssenCGMAnneJCauwenberghGDesmyterJHeykantsJJanssenMACDe ClercqE & JanssenPAJ (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA90:1711–1715.
22.
PremanathanMNakashimaHKathiresanKRajendranN & YamamotoN (1996) In vitro anti human immunodeficiency virus activity of mangrove plants. Indian Journal of Medical Research103:278–281.
23.
PremanathanMNakashimaHIgarashiRMizushimaY & YamadaK (1997) Lecithinized superoxide dismutase: an inhibitor of human immunodeficiency virus replication. AIDS Research and Human Retroviruses13:283–290.
24.
RichmanDDShihC-KLowyIRoseJProdanovichPGoffS & GriffinJ (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA88:11241–11245.
25.
RichmanDDHavlirDCorbeilJLooneyDIgnacioCSpectorSASullivanJCheesemanSBarringerKPaulettiDShihC-KMyersM & GriffinJ (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology68:1660–1666.
26.
ScholsDBabaMPauwelsR & De ClercqE (1989) Flow cytomet-ric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells. Journal of Acquired Immune Deficiency Syndromes2:10–15.
27.
SekiMSadakataYYuasaS & BabaM (1995) Isolation and characterization of human immunodeficiency virus type 1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-422. Antiviral Chemistry and Chemotherapy6:73–79.
28.
StaszewskiSMillerVKoberAColebundersRVandercamBDelescluseJClumeckNWanzeeleFVDe BrabanderMDe CreeJMoeremansMAndriesKBoucherCStoffelsPJanssenPAJ & members of the Loviride Collaborative Study Group (1996a) Evaluation of the efficacy and tolerance of R018893, R089439 (loviride) and placebo in asymptomatic HIV-1 infected patients. Antiviral Therapy1:42–50.
29.
StaszewskiSMillerVRehmetSStarkTDe CreeJDe BrabanderMPeetersMAndriesKMoeremansMDe RaeymaekerMPearceGVan Den BroeckRVerbiestW & StoffelsP (1996b) Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS10:F1–F7.
30.
WlodekLRommelspacherHSusiloRRadomskiJ & HofleG (1993) Thiazolidine derivatives as source of free L-cysteine in rat tissue. Biochemical Pharmacology46:1917–1928.
